FDA extends review period for Ascendis Pharma's first drug
Ascendis Pharma has to wait three more months for the FDA to give its verdict on the firm's drug lonapegsomatropin for treating pediatric growth hormone deficiency.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Just two weeks before the deadline, the US Food and Drug Administration (FDA) has extended the review period for Ascendis Pharma's first drug candidate lonapegsomatropin, according to an Ascendis Pharma press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis increases expenses shortly before moment of truth
For subscribers
.jpg&w=384&q=75)
